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Abstract: Growing evidence supports the role of probiotics in reducing the risk of necrotizing
enterocolitis, time to achieve full enteral feeding, and late-onset sepsis (LOS) in preterm infants.
As reported for several neonatal clinical outcomes, recent data have suggested that nutrition might
affect probiotics’ efficacy. Nevertheless, the currently available literature does not explore the
relationship between LOS prevention and type of feeding in preterm infants receiving probiotics.
Thus, the aim of this systematic review and meta-analysis was to evaluate the effect of probiotics
for LOS prevention in preterm infants according to type of feeding (exclusive human milk (HM)
vs. exclusive formula or mixed feeding). Randomized-controlled trials involving preterm infants
receiving probiotics and reporting on LOS were included in the systematic review. Only trials
reporting on outcome according to feeding type were included in the meta-analysis. Fixed-effects
models were used and random-effects models were used when significant heterogeneity was found.
The results were expressed as risk ratio (RR) with 95% confidence interval (CI). Twenty-five studies
were included in the meta-analysis. Overall, probiotic supplementation resulted in a significantly
lower incidence of LOS (RR 0.79 (95% CI 0.71–0.88), p < 0.0001). According to feeding type, the
beneficial effect of probiotics was confirmed only in exclusively HM-fed preterm infants (RR 0.75
(95% CI 0.65–0.86), p < 0.0001). Among HM-fed infants, only probiotic mixtures, and not single-strain
products, were effective in reducing LOS incidence (RR 0.68 (95% CI 0.57–0.80) p < 0.00001). The results
of the present meta-analysis show that probiotics reduce LOS incidence in exclusively HM-fed preterm
infants. Further efforts are required to clarify the relationship between probiotics supplementation,
HM, and feeding practices in preterm infants.
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1. Introduction
Late onset sepsis (LOS) is one of the most common causes of morbidity and mortality in preterm
infants [1,2]. It occurs in approximately 20% of very low birth weight (VLBW) infants, has a significant
overall mortality [3], and a high risk of long-term neurodevelopmental sequelae [4].
Beyond an immature skin-mucosal barrier and immune response, other well-recognized risk
factors for LOS include long-term use of invasive interventions, failure of early enteral feeding with
breast milk, prolonged duration of parenteral nutrition, hospitalization, surgery, and underlying
respiratory and cardiovascular diseases [2].
Growing evidence supports the key role of a healthy gut microbiota in promoting and maintaining
a balanced immune response and in the establishment of the gut barrier in the immediate postnatal
life [5]. However, in preterm infants, the development of the microbial community is disrupted by
events related to prematurity: Mode of delivery, antenatal and postnatal use of antibiotics, minimal
exposure to maternal flora, and low intake of breast milk [6]. Such disruption, called dysbiosis, results
in an altered barrier and immune function and an imbalance between pro- and anti-inflammatory
responses, and has been associated with necrotizing enterocolitis (NEC) and LOS [7,8].
Probiotics, defined as live micro-organisms that confer health benefits to the host through
an interaction with gut microbiota and immune function when administered at adequate doses [9],
have been proposed as potential tools to prevent NEC and LOS [10].
Updated meta-analyses confirm the benefits of probiotics in reducing the risk of NEC [11,12], the
time to achieve full enteral feeding [13,14], and the risk of LOS [15,16] in preterm infants. However,
most of these meta-analyses fail to explore the role of probiotics in deeper detail, and do not provide
specific recommendations regarding which probiotic strain or mixture of strains should be used, and
which population would benefit most from the use of probiotics.
Gut colonization in human milk (HM)-fed preterm infants is different from that of formula-fed
infants [17]. HM provides nutrients, prebiotic carbohydrates, endogenous probiotics, and a variety
of bioactive factors that exert beneficial effects directly and indirectly on host-gut microbiota
interactions [18]. Recent data suggest that probiotic efficacy might be dependent upon the type
of feeding; specifically, only preterm infants receiving HM would benefit from probiotic use in terms
of a lower risk of NEC [19] and a reduction in the time needed to achieve full enteral feeding [13].
Furthermore, in vitro studies have shown that the growth of some probiotic species is enhanced in
the presence of HM oligosaccharides (HMOs) [20,21]. Despite these suggestions, however, only a few
randomized controlled trials (RCTs) report the type of feeding in infants given probiotics; and also for
this reason, meta-analyses are unable to make any consideration about the influence of type of feeding
in reducing adverse outcomes, such as NEC or LOS, in preterm infants receiving probiotics [13,16].
The aim of this systematic review and meta-analysis is thus to evaluate the effect of probiotics for
the prevention of LOS in preterm infants according to type of feeding (exclusive HM vs. exclusive
formula or mixed feeding).
2. Materials and Methods
2.1. Literature Search
The study protocol was designed by the members of the Task Force on Probiotics of the Italian
Society of Neonatology. A systematic review of published studies reporting the use of probiotics for
the prevention of LOS in preterm infants, according to type of feeding, was performed in accordance
with PRISMA guidelines [22].
The characteristics of the studies included in the systematic review were the following:
Randomized and quasi-randomized controlled trials involving preterm infants (gestational age (GA)
<37 weeks) who had received, within one month of age, any probiotic compared to placebo or no
treatment. The outcome of interest was culture-proven LOS, defined as the presence of a positive blood
or cerebrospinal fluid culture taken >72 h after birth.
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PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), the Cochrane Library (http://www.
cochranelibrary.com/) and Embase (http://www.embase.com/) were interrogated for studies
published before 28 October 2016. The following string was used to perform the PubMed search:
((infant OR infants) OR (neonate OR neonates) OR (newborn OR newborns) AND (septi* OR sepsi* OR
sepsis) OR (bacterial infect* OR bacterial infections (MH)) AND (probiotic OR probiotics OR pro-biotic
OR pro-biotics)) NOT (animals (MH) NOT humans (MH)). The string was built up by combining
all the terms related to LOS and probiotics, using PubMed MeSH terms, free-text words, and their
combinations through the most proper Boolean operators, in order to be as comprehensive as possible.
Similar criteria were used for searching the Cochrane Library and Embase. The review was restricted
to English-written studies involving human subjects.
Luca Maggio (LM), Giovanni Barone (GB), Arianna Aceti (AA), and Isadora Beghetti (IB)
performed the literature search. Potentially eligible studies were identified from the abstracts; the
full texts of relevant studies were assessed for inclusion and their reference lists were searched for
additional studies.
2.2. Data Extraction and Meta-Analysis
Study details (population, characteristics of probiotic and placebo, type of feeding, and outcome
assessment) were evaluated independently by LM, GB, AA, and IB, and checked by Davide Gori (DG).
Study quality was evaluated independently by AA, IB, and DG using the risk of bias tool as proposed
by the Cochrane collaboration (Chapter 8 of the Cochrane Handbook of Systematic Reviews) [23].
In addition, an assessment of the quality of evidence using the GRADE working group approach
was performed [23]. The evaluation was carried out by DG following Chapter 12 of the Cochrane
Handbook [23] and classifying the evidence as high, moderate, low, and very low (as suggested by the
GRADE Working Group) [24].
When outcome data were not reported according to type of feeding, the corresponding authors
of the papers were contacted by email and were asked to provide separate data for LOS incidence
in infants receiving probiotics vs. placebo according to type of feeding (exclusive HM vs. exclusive
formula or mixed feeding). If the corresponding author was unable to provide these data or did not
reply to the email, the paper was excluded from the meta-analysis.
The association between probiotic use and LOS was evaluated by a meta-analysis conducted
by AA, IB, and DG using the RevMan software (version 5.3, downloaded on 1 November 2016 from
the Cochrane website: http://tech.cochrane.org/revman/download). Risk ratio (RR) was calculated
using the Mantel–Haenszel method and reported with a 95% confidence interval (CI). A fixed-effect
model was used for the analyses. Heterogeneity was assessed using the χ2 test and I2 statistic: If
significant heterogeneity was found (p < 0.05 from the χ2 test) or the number of studies was lower than
five, a random-effects model was used instead [23].
The results of the meta-analysis were presented using forest plots, while a funnel plot was used
for investigating publication bias.
3. Results
3.1. Literature Search
The number of potentially relevant papers identified through the literature search was 2713
(1401 in PubMed, 83 in the Cochrane Library, and 1229 in Embase).
As shown in Figure 1, 68 papers met the inclusion criteria (35 in PubMed, 13 in the Cochrane
Library search, and 20 in Embase). Four additional studies were identified by a manual search of the
reference lists of included studies. Among these 72 studies, 32 were excluded as they were duplicates
retrieved by at least two search engines. Three studies were excluded after examining the full texts:
One study included both term and preterm infants [25], one study reported supplementation with
probiotic plus bovine lactoferrin [26], and one study was not written in English [27].
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reported  in Table 3. The study by Dutta et al.  [37] was  reported  three  times, as  it  included  three 
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exclusively formula‐fed infants [31,32,61,64]. 
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compared  to  infants  in  the  control  group  (399  (13.60%)  vs.  506  (17.24%),  respectively). Probiotic 
Figure 1. Flow chart of the search strategy and search results. The relevant number of papers at each
point is given.
Finally, 37 studies were eligible for the syst matic review [28–64]. Details of the included s udies
are reported in Table 1; excluded studies are d scribed in Table 2.
Table 1. Studies incl ed in the syst matic review.
Author, Year Study Details Study Population
Intervention Specie
Placebo
Dose (D)
Start of Treatment (S)
End of Treatment (E)
Al-Hosni, 2012 [28]
P
Preterm infants with BW
501–1000g,
appropriate f r g stational age,
and ≤ 14 days of age at time of
feeding initiation
Lactobacillus rhamnosus GG
Bifidobacterium Infantis
Extra milk
DB D: 0.5 × 10
9 CFU e h
probiotic, OD
R S: first enteral feeding
C E: discharge or until 34 wpostmenstrual age
Multic.
Bin-Nun, 2005 [29]
P
Preterm infants with BW < 1500g,
who began enteral feeding on a
weekday
Bifidobacterium infantis
Streptococcus thermophileus
Bifidobacterium bifidus
HM or FMB D: 0.35 × 10
9 CFU each
probiotic, OD
R S: Start of enteral feeding
C E: 36 w postconceptual age
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Table 1. Cont.
Author, Year Study Details Study Population
Intervention Specie
Placebo
Dose (D)
Start of Treatment (S)
End of Treatment (E)
Braga, 2011 [30]
P
Inborn infants with BW
750–1499 g
Lactobacillus casei
Bifidobacterium breve
Extra HM
DB D: 3.5 × 10
7 CFU to
3.5 × 109 CFU OD
R S: Day 2
C
E: Day 30, NEC diagnosis,
discharge, death whichever
occurred first
Chrzanowska-Liszewska,
2012 [31]
P
Preterm infants with GA< 32 w
and BW> 1000g, who started
enteral formula feeding before
enrollment
Lactobacillus rhamnosus
MDX
DB D: 6 × 109 CFU, OD
R S: Day 0–3 of life
C E: Day 42 of supplementation
Costalos, 2003 [32]
P
GA 28–32 w
No major GI problem
Not receiving antibiotics
Not receiving breast milk
Saccharomyces boulardii
MDX
R D: 1×109 CFU BD
C S: Non-specified
Median duration of probiotic
supplementation: 30 days
Costeloe, 2016 [33]
P
Preterm infants with GA 23–30 w
No severe malformation or any
GI tract
Malformation
Bifidobacterium breve BBG-001
Corn starch
B D: 8.3–8.8 log10
R S: 43.9 h (median age)
C E: 36 weeks’ postmenstrualage or discharge
Multic.
Dani, 2002 [34]
P
Infants with GA< 33 w or
BW < 1500 g
Lactobacillus rhamnosus GG
MDX
DB D: 6×109 CFU OD
R S: First feed
C E: Discharge
Multic.
Demirel, 2013 [35]
P
Preterm infants with GA≤ 32 w
and BW≤ 1500 g, who survived to
feed enterally
Saccharomyces boulardii
None
B D: 5 × 109 CFU OD
R S: First feed
C E: Discharge
Dilli, 2015 [36]
P
Preterm infants with GA< 32 w
and BW< 1500 g, born at or
transferred to the NICU within
the first week of life and fed
enterally before inclusion
Bifidobacterium lactis
MDX powder
DB D: 5 × 109 CFU
R S: Beyond d7 after birth
C E: Death or discharge (max8 weeks)
Multic
Dutta, 2015 [37]
P Preterm infants with GA 27–33 w,
< 96 h of age,
tolerating milk
≥ 15 mL/kg/day
No GI/life-threatening
malformations
No NEC/sepsis
Lactobacillus acidophilus
Lactobacillus rhamnosus
Bifidobacterium longum
Saccharomyces boulardii Potato starch,
MDX,
magnesium
stearate.
B Total D: 10
10 CFU (high dose)
or 109 CFU (low dose), BD
R S: Age< 96 h
C E: Day 14 (short course) orday 21 (long course)
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Table 1. Cont.
Author, Year Study Details Study Population
Intervention Specie
Placebo
Dose (D)
Start of Treatment (S)
End of Treatment (E)
Fernandez-Carrocera,
2013 [38]
P
Preterm infants with BW< 1500g
Lactobacillus acidophilus
1 CFU/g
Lactobacillus rhamnosus
4.4 × 108 CFU/g
Lactobacillus casei
1 × 109 CFU/g
Lactobacillus plantarum
1.76 × 108 CFU/g
Bifidobacterium infantis
2.76 × 107 CFU/g
Streptococcus thermophilus
6.6 × 105 CFU/g
None
DB Total D: 1g powder OD
R S: Start of enteral feeding
C E: Non-specified
Hays, 2015 [39]
P Preterm infants with GA 25–31 w
and BW 700–1600,
AGA, admitted to hospital within
day 7 of life,
Who initiated enteral feeding
before day 5.
Infants with NEC ≥ IB were
excluded
No severe malformation
No severe clinical or surgical
condition
Bifidobacterium lactis only
Bifidobacterium longum only
Bifidobacterium lactis +
Bifidobacterium longum
MDX
DB D: 109 CFU each strain, OD
R S: Non-specified
C
Duration: 4 weeks if
GA≥ 29 w , 6 weeks if
GA≤ 28 w or until feeding
interruption for more than
72 h
Multic.
Hikaru, 2012 [40]
P
Extremely preterm infants and
VLBW infants
No major gastrointestinal tract
surgery or multiple anomalies
Bifidobacterium breve
None
R D: 109 CFU, OD
C S: Day of birth
E: Discharge
Jacobs, 2013 [41]
P
Preterm infants with GA< 32 w
and BW< 1500 g
Bifidobacterium infantis BB-02
300 CFU × 106
Streptococcus thermophilus Th-4
350 CFU × 106
Bifidobacterium lactis BB-12 350
CFU × 106
MDX powder
DB Total D: 1 × 10
9 CFU × 1.5 g
maltodextrin powder OD
R S: enteral feed ≥ 1 mLevery 4 h
C E: discharge or termcorrected age
Multic.
Kanic, 2015 [42]
P
Preterm infants with GA< 33 w
and BW< 1500 g
Lactobacillus acidophilus
Enterococus faecium
Bifidobacterium infantis
NoneR Total D: 0.6 × 107 CFU, BD
C S: Start of enteral feeding
E: Discharge
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Table 1. Cont.
Author, Year Study Details Study Population
Intervention Specie
Placebo
Dose (D)
Start of Treatment (S)
End of Treatment (E)
Kitajima, 1997 [43]
P
Preterm infants with BW< 1500 g
Bifidobacterium breve YIT4010
Distilled water
R D: 0.5 × 109 CFU OD
C S: Within 24 h of life
Duration of probiotic
supplementation: 28 days
Lin, 2005 [44]
P
Infants with BW< 1500 g, who
started to feed enterally and
survived beyond day 7
Lactobacillus acidophilus
None
Bifidobacterium infantis
B D: ≥ 10
6 CFU each probiotic
(= 125 mg/kg), BD
R S. Start of enteral feeding
C E: Discharge
Lin, 2008 [45]
P
Preterm infants with GA< 34 w
and BW< 1500 g,
who survived to feed enterally
Lactobacillus acidophilus
NCDO 1746
Bifidobacterium bifidum
NCDO 1453
NoneB
D: 1 × 109 CFU each probiotic
(= 125 mg/kg), BD
R S: Day 2 of age
C Duration: 6 weeks
Multic.
Manzoni, 2006 [46]
P
Infants with BW< 1500 g,
≥ 3 days of life, who started
enteral feeding with HM
Lactobacillus rhamnosus LGG
None
DB D: 6 × 109 CFU/day
R S: Day 3 of life
C E: End of the 6th week ordischarge
Mihatsch, 2010 [47]
P
Preterm infants with GA< 30 w
and BW≤ 1500 g
Bifidobacterium lactis BB12
Indistinguishable
powder
R D: 2 × 10
9 CFU/kg 6 times
a day
C S: Start of enteral feeding
E: Non-specified
Millar, 1993 [48]
P
Preterm infants with GA≤ 33 w
Lactobacillus GG
None
DB D: 108 CFU, BD
R S: Start of enteral feed
Duration: 14 days
Oncel, Sari, 2013 [49]
P
Preterm infants with GA≤ 32 w
and BW≤ 1500 g,
who survived to feed enterally
Lactobacillus reuteri DSM 17938
Oil base
DB D: 1 × 108 CFU OD
R S: First feed
C E: Death or discharge
Partty, 2013 [50]
P
Preterm infants with GA 32–36 w
and BW> 1500 g
Lactobacillus rhamnosus GG Microcrystal
line
cellulose and
dextrose
anhydrate
DB D: 1 × 109 CFU
R S: Day 1
C E: OD until day 30, BD untilday 60
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Table 1. Cont.
Author, Year Study Details Study Population
Intervention Specie
Placebo
Dose (D)
Start of Treatment (S)
End of Treatment (E)
Patole, 2014 [51]
P
Preterm infants with GA< 33 w
and BW< 1500 g
Bifidobacterium breve M16-V
DextrinDB
D: 3 × 109 CFU OD (1.5 × 109
CFU OD for newborns≤ 27 w
until they reached 50
ml/kg/day enteral feeds)
R S: Start of enteral feed
C E: Corrected age of 37 w
Rojas, 2012 [52]
P
Preterm infants with BW≤ 2000 g,
hemodynamically stable, ≤ 48 h
of age (regardless start of enteral
feeding)
Lactobacillus reuteri DSM 17938
Oil base
DB D: 1 × 108 CFU OD
R S: Age≤ 48 h
C E: Death or discharge
Multic.
Romeo, 2011 [53]
P
Preterm infants with GA< 37 w
and BW< 2500g, who reached
stable enteral feeding within 72 h
of life
Lactobacillus reuteri ATCC
55730, 1 × 108 CFU OD
NoneR
Lactobacillus rhamnosus ATCC
53103, 6 × 109 CFU OD
C S: Within 72 h of life
E: After 6 w or at discharge
Rougé, 2009 [54]
P Preterm infants with GA< 32 w
and BW≤ 1500 g,
≤2 w of age, without any disease
other than those linked to
prematurity, who started enteral
feeding before inclusion
Bifidobacterium longum BB536
Lactobacillus rhamnosus GG
BB536-LGG
MDXDB Total D: 1 × 108 CFU/day
R S: Start of enteral feeding
C E: Discharge
Bic.
Roy, 2014 [55]
P
Preterm infants with GA< 37 w
and BW< 2500 g
Lactobacillus acidophilus
1.25 × 109 CFU
Bifidobacterium longum
0.1250 × 109 CFU
Bifidobacterium bifidum
0.125 × 109 CFU
Bifidobacterium lactis
1 × 109 CFU
Sterile water
R Total D: 0.5 g powder, BD
DB S: Within 72 h of life
C E: After 6 w or at discharge
Saengtawesin, 2014 [56]
P
Preterm infants with GA≤ 34 w
and BW≤ 1500g
Lactobacillus acidophilus
1 × 109 CFU
Bifidobacterium bifidum
1 × 109 CFU
NoneR Total D: 125 mg/kg BD
C S: Start of enteral feeding
E: End of 6th w of
supplementation or discharge
Samanta, 2009 [57]
P
Preterm infants with GA< 32 w
and BW< 1500g,
Who started to feed enterally and
survived beyond 48 h of life
Bifidobacterium infantis
Bifidobacterium bifidum
Bifidobacterium longum
Lactobacillus acidophilus
None
DB D: 2.5 × 10
9 CFU each
probiotic, BD
R S: Non specified
C E: Discharge
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Author, Year Study Details Study Population
Intervention Specie
Placebo
Dose (D)
Start of Treatment (S)
End of Treatment (E)
Sari, 2011 [58]
P
Preterm infants with GA< 33 w
and BW< 1500 g,
Who survived to feed enterally
Lactobacillus sporogenes
None
B D: 0.35 × 109 CFU, OD
R S: Start of enteral feeding
C E: Discharge
Serce, 2013 [59]
P
Preterm infants with GA≤ 32 w
and GA≤ 1500g,
who survived to feed enterally
Saccharomyces boulardii
Distilled water
DB D: 0.5 × 109 CFU, BD
R S: Start of enteral feeding
C E: Discharge
Sinha, 2015 [60]
P
Preterm infants with GA≥ 34 w
and BW 1500–2500 g
Streptococcus thermophiles
Bifidobacterium breve
Bifidobacterium longum
Bifidobacterium infantis
Lactobacillus acidophilus
Lactobacillus plantarum
Lactobacillus paracasei
Lactobacillus delbrueckii spp
bulgaricus
MDX
DB Total D: 10 × 109 CFU per day
R S: Day 3 of life
C Duration: 30 days
Bic.
Stratiki, 2007 [61]
P
Preterm infants with GA 27–37 w,
formula fed
Bifidobacterium lactis
None
B D: 2 × 10
7 CFU/ g
milk powder
R S: Start of enteral feeding
C E: Discharge
Tewari, 2015 [62]
P
Preterm infants with GA< 34 w
Bacillus clausii
Sterile water
DB D: 2.9 × 109 spores
R S: D5 in asymptomatic, d10 insymptomatic infants
C
E: 6 w of life, discharge, death,
LOS diagnosis, whichever
occurred first
Totsu, 2014 [63]
P
Infants with BW< 1500 g
Bifidobacterium bifidum
Dextrin
DB D: 2.5 × 10
9 CFU, divided in
two doses
CLR S: Within 48 h after birth
C E: Body weight 2000 g
Multic.
Xu, 2016 [64]
P
Preterm infants with GA> 30 and
BW 1500–2500 g, formula fed
Saccharomyces boulardii
None
B D: 109 CFU/Kg , BD
R S: Start of enteral feeding
C E: 28th day of life or discharge
B: Blinded, BD: Twice a day, Bic: Bicentric, BW: Birth weight, C: Controlled, CLR: Cluster-randomized,
CFU: Colony forming units, DB: Double-blinded, DM: Donor milk, g: Grams, FM: Formula, GA: Gestational age,
GI: Gastrointestinal, h: Hours, HM: Human milk, HMF: Human milk fortifier, LOS: Late onset sepsis, M: Masked,
MDX: Maltodextrin, Multic: Multicentric, NEC: Necrotizing enterocolitis, OD: Once daily, OMM: Own mother’s
milk, P: Prospective, PFM: Preterm formula, R: Randomized, w: Weeks
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Table 2. Studies excluded from the systematic review.
Authors, Year Study Summary Reason for Exclusion
Awad, 2000 [25] Living vs. killed Lactobacillus acidophilus vs. placebo given toneonates admitted to the study NICU Term and preterm infants included
Manzoni, 2009 [26] Bovine Lactoferrin (BLF) alone or BLF plusLactobacillus rhamnosus GG given to VLBW neonates
Supplementation with probiotic
and lactoferrin
Ren B, 2010 [27] Bacillus clausii and Clostridium (butyricum) San Chang LeKang given to preterm infants (exact gestational age unclear) Non English-written study
NICU neonatal intensive care unit, VLBW very low birth weight.
For each included study, the LOS rate in the probiotic and in the placebo/control group
is reported in Table 3. The study by Dutta et al. [37] was reported three times, as it included
three groups of patients supplemented with a probiotic given at three different doses. Data from
the study of Hays et al. [39] were reported three times because three different interventions
(Bifidobacterium lactis alone, Bifidobacterium longum alone, and B. lactis plus B. longum) were evaluated.
The study by Romeo et al. [53] was reported twice, as it compared two different probiotics to
placebo (Lactobacillus reuteri ATCC 55730 and Lactobacillus rhamnosus ATCC 53103), and the one
by Tewari et al. [62] was reported twice because its participants were stratified as very preterm and
extremely preterm.
Table 3. Incidence of late-onset sepsis (LOS) in infants treated with probiotics and in control.
Author, Year Previous LOSRate
Number of
Subjects
LOS in Probiotic
Group
LOS in Control
Group
Al-Hosni, 2012 [28] Not stated 50 probiotic51 control 13/50 16/51
Bin-Nun, 2005 [29] Not stated 72 probiotic73 control 31/72 24/73
Braga, 2011 [30] Not stated 119 probiotic112 placebo 40/119 42/112
Chrzanowska-Liszewska, 2012 [31] Not stated 21 probiotic26 placebo 2/21 3/26
Costalos, 2003 [32] Not Stated 51 probiotic36 placebo 3/51 3/36
Costeloe, 2015 [33] 15% 650 probiotic660 placebo 73/650 77/660
Dani, 2002 [34] Not stated 295 probiotic290 placebo 14/295 12/290
Demirel, 2013 [35] Not stated 135 probiotic136 control 20/135 21/136
Dilli, 2015 [36] Not stated 100 probiotic100 placebo 8/100 13/100
Dutta, 2015 A [37] Not stated 38 probiotic35 placebo 3/38 6/35
Dutta, 2015 B [37] Not stated 38 probiotic35 placebo 1/38 6/35
Dutta, 2015 C [37] Not stated 38 probiotic35 placebo 6/38 6/35
Fernández-Carrocera, 2013 [38] Not stated 75 probiotic75 placebo 42/75 44/75
Hays, 2015 P1 [39] Not stated 50 probiotic52 placebo 9/50 10/52
Hays, 2015 P2 [39] Not stated 48 probiotic52 placebo 8/48 10/52
Hays, 2015 P3 [39] Not stated 47 probiotic52 placebo 8/47 10/52
Hikaru, 2012 [40] Not stated 108 probiotic100 control 10/108 22/100
Jacobs, 2013 [41] 23% 548 probiotic551 placebo 72/548 89/551
Kanic, 2015 [42] Not stated 40 probiotic40 control 16/40 29/40
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Author, Year Previous LOSRate
Number of
Subjects
LOS in Probiotic
Group
LOS in Control
Group
Kitajima, 1997 [43] Not stated 45 probiotic46 placebo 1/45 0/46
Lin, 2005 [44] Not stated 180 probiotic187 control 22/180 36/187
Lin, 2008 [45] Not stated 217 placebo217 control 40/217 24/217
Manzoni, 2006 [46] Not stated 39 probiotic41 control 19/39 22/41
Mihatsch, 2010 [47] 40% 91 probiotic89 placebo 28/91 29/89
Millar, 1993 [48] Not stated 10 probiotic10 control 0/10 0/10
Oncel, Sari 2013 [49] Not stated 200 probiotic200 placebo 13/200 25/200
Partty, 2013 [50] Not stated 31 probiotic32 placebo 0/31 0/32
Patole, 2014 [51] Not stated 77 probiotic76 placebo 17/77 12/76
Rojas, 2012 [52] 28% 372 probiotic378 placebo 24/372 17/378
Romeo, 2011 A [53] Not stated 83 probiotic83 control 1/83 9/83
Romeo, 2011 B [53] Not stated 83 probiotic83 control 2/83 9/83
Rougé, 2009 [54] Not stated 45 probiotic49 placebo 15/45 13/49
Roy, 2014 [55] 33% 56 probiotic56 placebo 31/56 42/56
Saengtawesin, 2014 [56] Not stated 31 probiotic29 control 2/31 1/29
Samanta, 2009 [57] Not stated 91 probiotic95 control 13/91 28/95
Sari, 2011 [58] Not stated 110 probiotic111 control 29/110 26/111
Serce, 2013 [59] 19% 104 probiotic104 placebo 19/104 25/104
Sinha, 2015 [60] 17% 668 probiotic672 placebo 38/668 54/672
Stratiki, 2007 [61] Not stated 41 probiotic36 control 0/41 3/36
Tewari, 2015 E [62] 21% 61 probiotic59 placebo 6/61 8/59
Tewari, 2015 V [62] 21% 62 probiotic62 placebo 2/62 3/62
Totsu, 2014 [63] Not stated 153 probiotic130 placebo 6/153 10/130
Xu, 2016 [64] Not stated 51 probiotic49 control 4/51 6/49
Among the eligible studies, only twelve reported LOS according to feeding type during the
study period: Eight studies reported LOS in exclusively HM-fed infants, either own mother’s milk
(OMM) or donor human milk (DHM) [30,43,44,46,55,57,60,62], while four studies included exclusively
formula-fed infants [31,32,61,64].
The corresponding authors of the remaining twenty-five studies were contacted by e-mail: data
were provided for thirteen studies [28,36–39,42,49–52,56,58,59].
Twenty-five [28,30–32,36–39,42–44,46,49–52,55–62,64] studies were finally suitable for inclusion
in the meta-analysis.
3.2. Probiotic and LOS: Overall Population
Overall, data from 5868 infants (2934 in the probiotic group and 2934 in the control group) were
evaluated. Regardless of type of feeding, fewer infants in the probiotic group developed LOS compared
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to infants in the control group (399 (13.60%) vs. 506 (17.24%), respectively). Probiotic supplementation
resulted in a significantly lower incidence of LOS (RR 0.79 (0.71–0.88), p < 0.0001; Figure 2a).
Number needed to treat was 28. In other words, 28 infants would need to receive probiotic
supplementation in order to prevent one additional case of LOS. The funnel plot did not show
any clear asymmetry (Figure 2b).
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Figure 2. Forest plot (a) and funnel plot (b) of the included studies. The forest plot shows the
association between the use of probiotics and late onset sepsis in the overall population of preterm
infants. The evaluation of the overall results of the meta-analysis according to the GRADE approach
is reported below the forest plot. The funnel plot does not show any clear visual asymmetry. M–H:
Mantel–Haenszel method; RR, risk ratio; CI, confidence interval.
3.3. Probiotic and LOS According to Type of Feeding
The data were then analyzed according to type of feeding (exclusive HM, exclusive formula, or
mixed feedi g).
Twenty studies [28,30,36–38,42–44,46,49–52,55–60,62] provided data for 3402 exclusively HM-fed
infants (1705 in the probiotic and 1697 in the control group). LOS occurred less frequently in HM-fed
infants receiving probiotics than in controls (231 (13.55%) infants vs. 307 (18.09%), respectively); the
RR was 0.75 ((95% CI 0.65–0.86), p < 0.0001), and heterogeneity among studies was absent (Figure 3).
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Figure 3. The forest plot shows the association between the use of probiotics and late onset
sepsis in the twenty studies reporting data for exclusively human milk-fed preterm infants. M–H:
Mantel–Haenszel method.
Sixteen [28,31,32,36–38,42,49–52,56,58,59,61,64] studies provided data for 800 exclusively
formula-fed infants (398 in the probiotic and 402 in the control group). The difference in LOS incidence
between groups was not significant (RR 0.77 (95% CI 0.51–1.17), p = 0.22; Figure 4).
Figure 4. The forest plot shows the association between the use of probiotics and late onset
sepsis in the sixteen studies reporting data for exclusively formula-fed preterm infants. M–H:
Mantel–Haenszel method.
Thirteen [28,36–39,42,49–52,56,58,59] st ies ro i ed data for 1271 infants receiving mixed
feeding (626 in the probiotic and 645 in the control group). The difference in LOS incidence between
groups was not significant (RR 0.85 (95% CI 0.69–1.05), p = 0.13; Figure 5).
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In order to examine in deeper detail the effect of probiotics in HM-fed infants, sub-meta-analyses
restricted according to population and probiotic characteristics, as well as study quality,
were performed.
3.3.1. Population Characteristics: VLBW and Extremely Low Birth Weight (ELBW) Infants
Fifteen [28,36,38,42–44,46,49,51,52,56–59,62] studies reported data for 1516 exclusively HM-fed
VLBW infants (760 in the probiotic and 756 in the control group). LOS occurred less frequently in
infants given probiotics than in controls (114 (15%) infants vs. 151 (19.97%)), with an RR of 0.76
(95% CI 0.62–0.94; p = 0.01; I2 = 0%; fixed-effect model).
Only two studies reported specific data on LOS in ELBW infants. One study [28] included only
ELBW infants, who received exclusive HM or mixed feeding; the other one [62] recruited both VLBW
and ELBW infants, who were exclusively HM-fed. In these studies, probiotic supplementation did not
show any significant benefit in terms of LOS compared to a placebo.
3.3.2. Probiotic Characteristics
Ten studies [28,30,37,38,42,44,55–57,60] reported data for 2560 HM-fed infants who received
a probiotic mix (1281 infants) vs. placebo/no treatme t (1279 infants). LOS occurred less frequently
in infants given probiotics than in controls (169 (13 2%) infants vs. 242 (18.9%)), with an RR of 0.68
(95% CI 0.57–0.80; p < 0.000 1; I2 = 0%; fixed-ef ect model).
Four st dies [46,49,50,52] reported d ta for 175 HM-fed infants who receiv d a single-strain
Lactobacillus probiotic (91 infants) vs. placebo/no treatment (84 infants). No difference between groups
in the incidence of LOS was documented (RR 0.87 (95% CI 0.58–1.32); p = 0.63; I2 = 0%; random
effects model). Lactobacillus strains differed among studies: Lactobacillus rhamnosus was used in two
studies [46,50] and Lactobacillus reuteri in two studies [49,52]. Lactobacillus sporogenes was used in one
study [58], showing no differences between groups in LOS incidence; this latter study was not included
in the pooled analysis, as L. sporogenes is a species which has not found international recognition,
shows characteristics of both genera Lactobacillus and Bacillus, and its strain should be better classified
as Bacillus coagulans [65].
Three studies [36,43,51] reported data for 334 HM-fed infants who received a single-strain
Bifidobacterium probiotic (174 infants) vs. placebo/no treatment (160 infants). No difference between
groups in the incidence of LOS was docu ented (RR 1.23 (95% CI 0.70–2.18); p = 0.47; I2 = 0%; random
effects model). Bifidobacterium strains differed among studies: Bifidobacterium breve was used in two
studies [43,51] and Bifidobacterium lactis in one study [36].
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Saccharomyces boulardii was used in one study [59], as well as Bacillus clausii [62]: None of these
studies showed a significant difference between infants treated with probiotics and controls in the
incidence of LOS.
3.4. Methodological Study Quality
The quality assessment of the studies included in the meta-analysis according to the risk of bias
tool as proposed by the Cochrane collaboration is shown in Figure 6. The last column of the Figure
also shows the assessment of the body of evidence using the GRADE working group approach.
Following a methodology similar to that used in the meta-analysis by Rao et al. [15], we conducted
a sensitivity analysis including only studies which had a low risk of bias in both random sequence
generation and allocation concealment. Sixteen studies [30–32,36,38,39,44,46,50–52,57–60,62] were
included and reported data for 4628 infants (2306 in the probiotic and 2322 in the control group).
The results were similar to those of the overall meta-analysis: LOS occurred less frequently in infants
receiving probiotics than in controls (309 (13.4%) infants vs. 366 (15.76%)) with an RR of 0.85 (95% CI
0.75–0.97; p = 0.02; I2 = 0%; fixed effect model).
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4. Discussion
In line with the results of previous papers [15,16], the present meta-analysis showed an overall
benefit of probiotic supplementation for the prevention of LOS in preterm infants. However, when
data were analyzed according to type of feeding, the beneficial effect of probiotics in reducing LOS
was confirmed only in exclusively HM-fed preterm and VLBW infants, but not in infants receiving
formula. Statistical heterogeneity among studies was almost absent and a low risk of publication bias
was documented.
Two recent meta-analyses investigating the effect of probiotic supplementation on LOS in preterm
infants reported an overall decrease in the risk of LOS in infants receiving probiotics compared to
controls [15,16]. The studies included in the meta-analyses by Rao [15] and Zhang [16] are almost the
same as those included in our updated systematic review; in the majority of the studies, both HM- and
formula-fed infants were recruited, but no detailed data on the relationship between type of feeding
and outcome were published.
Several data suggest that the impact of the type of feeding on clinical outcome in preterm infants
is likely to be relevant [66]: It has been previously shown that HM feeding, per se, is associated with
a reduction of the risk of developing LOS [67] and with a shorter time to achieve full enteral feeding
in VLBW infants [68]. In addition, the use of probiotics in HM-fed, but not in formula-fed, infants
appears to be related to a lower risk of NEC [19] and an earlier achievement of full enteral feeding [13].
It is plausible that the effect of probiotics on clinical outcomes could be mediated by HM
properties [69]; actually, several HM components, including prebiotic HMOs, growth factors,
immunological factors, and probiotic bacteria, can drive the establishment of a beneficial gut microbiota.
In addition, HM can constitute the ideal soil for exogenous probiotics and promote a more effective
crosstalk among probiotics, gut microbiota, and the developing immune system.
According to the latest recommendations, all preterm infants should receive exclusive HM; OMM
is the best nutritional choice, and pasteurized DHM should be preferred to formula when OMM is
not available or is contraindicated [70]. However, providing an exclusive HM diet to preterm infants
presents a variety of challenges related to the prematurity itself and to hospitalization [71]. The term
“exclusive HM feeding” may cover a range of feeding practices beyond direct breastfeeding, such
as the use of fresh vs. frozen expressed breast milk given by bottle or tube feeding, the addition of
HM fortifiers, and a variable duration of exclusive HM feeding. As described for pasteurization [72],
some of these interventions might affect the nutritional and non-nutritional components of HM. In this
perspective, the beneficial effect of probiotic supplementation in exclusively HM-fed infants might be
related to a synergic action exerted by exogenous probiotics together with the prebiotic components of
HM, which could partially restore the symbiotic potential of breast milk.
The data about exclusively HM-fed infants were analyzed according to population and probiotic
characteristics in order to evaluate which preterm infants would benefit more from probiotic use and
which probiotic strain or mixture of strains would be more beneficial. While there is evidence that
probiotics are effective in reducing LOS in VLBW infants, no definite conclusion could be drawn for
ELBW infants, as only two studies reported specific data on LOS in these infants, who remain the
highest-risk and most vulnerable population.
The currently available literature does not provide a definite recommendation on which
probiotic strain or mixture would be more effective in reducing LOS. In the 25 included studies,
different probiotic strains and mixtures were used. Consistently with previous papers [12,16,73], our
meta-analysis indicated that a mixture of different probiotic strains might be more effective in reducing
LOS in exclusively HM-fed preterm infants. A possible explanation for this finding is that a probiotic
mixture would provide a better ecological barrier and a more diverse immunological stimulation than
a single strain.
The possible limitations of the present meta-analysis should be taken into consideration.
Thirty-seven studies were potentially eligible for the meta-analysis, but only 25 studies provided
separated data according to feeding type. In addition, infants’ classification according to feeding
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type was not homogeneous across studies, and the meta-analysis had to rely on unpublished
information provided by the authors themselves. Finally, although no statistical heterogeneity was
found, the characteristics of probiotic administration (dose, duration, time of initiation, and probiotic
micro-organisms) differed among the included studies.
More importantly, no separate data for OMM-fed and DHM-fed infants were available; as a result,
it was not possible to clarify whether the “synergic” effect of HM and probiotics applies to both
OMM and DHM. It remains also unclear whether HM feeding, either OMM or DHM, has a “dose and
time-dependent” effect on probiotic supplementation, as reported for outcomes such as NEC [66].
Probiotics appear to be generally safe, but it has to be acknowledged that there are some
reports about the occurrence of sepsis in preterm newborns potentially linked to probiotic
supplementation [74]. None of the studies included in the systematic review reported any side
effect related to probiotic administration.
5. Conclusions
According to the results of the present meta-analysis, probiotic supplementation reduces the risk
of LOS in exclusively HM-fed preterm infants. An exclusive HM diet should be the gold standard
for all preterm, VLBW infants. Since direct breastfeeding is almost impossible in this population, it is
likely that manipulations of HM, including pasteurization, refrigeration, and administration by tube or
bottle, could affect HM bioactive properties; in this context, the administration of exogenous probiotics
could help in restoring, at least partially, HM symbiotic properties.
Future research should be aimed at clarifying the relationship between feeding practices and
probiotic supplementation, and at addressing the choice of the most effective probiotic products to be
used in exclusively HM-fed infants.
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